116 related articles for article (PubMed ID: 31502898)
1. Efficacy of dasatinib against ponatinib-resistant chronic myeloid leukemia cells.
Okabe S; Tanaka Y; Moriyama M; Gotoh A
Leuk Lymphoma; 2020 Jan; 61(1):237-239. PubMed ID: 31502898
[No Abstract] [Full Text] [Related]
2. Ponatinib (Iclusig) for CML and Ph+ ALL.
Med Lett Drugs Ther; 2013 Sep; 55(1424):71-2. PubMed ID: 25970013
[No Abstract] [Full Text] [Related]
3. Ponatinib for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Narayanan V; Pollyea DA; Gutman JA; Jimeno A
Drugs Today (Barc); 2013 Apr; 49(4):261-9. PubMed ID: 23616953
[TBL] [Abstract][Full Text] [Related]
4. Ponatinib in the therapy of chronic myeloid leukemia.
Poch Martell M; Sibai H; Deotare U; Lipton JH
Expert Rev Hematol; 2016 Oct; 9(10):923-32. PubMed ID: 27590270
[TBL] [Abstract][Full Text] [Related]
5. BCR-ABL1 compound mutations drive ponatinib resistance.
Cancer Discov; 2014 Nov; 4(11):OF13. PubMed ID: 25367954
[TBL] [Abstract][Full Text] [Related]
6. The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib.
Parker WT; Yeung DT; Yeoman AL; Altamura HK; Jamison BA; Field CR; Hodgson JG; Lustgarten S; Rivera VM; Hughes TP; Branford S
Blood; 2016 Apr; 127(15):1870-80. PubMed ID: 26773037
[TBL] [Abstract][Full Text] [Related]
7. First-line dasatinib discontinuation in chronic myeloid leukaemia: another step towards an "operational cure".
Breccia M; Foà R
Lancet Haematol; 2020 Mar; 7(3):e182-e183. PubMed ID: 31978330
[No Abstract] [Full Text] [Related]
8. Efficacy of ponatinib against ABL tyrosine kinase inhibitor-resistant leukemia cells.
Okabe S; Tauchi T; Tanaka Y; Ohyashiki K
Biochem Biophys Res Commun; 2013 Jun; 435(3):506-11. PubMed ID: 23684619
[TBL] [Abstract][Full Text] [Related]
9. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Shamroe CL; Comeau JM
Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
[TBL] [Abstract][Full Text] [Related]
10. Clinical activity of ponatinib in patients with chronic myeloid leukemia in chronic phase with e1a2 transcripts.
Jain P; Romo CG; Khoury HJ; Kantarjian H; Cortes J
Haematologica; 2013 Nov; 98(11):e141-2. PubMed ID: 24186316
[No Abstract] [Full Text] [Related]
11. Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management.
Saussele S; Haverkamp W; Lang F; Koschmieder S; Kiani A; Jentsch-Ullrich K; Stegelmann F; Pfeifer H; La Rosée P; Goekbuget N; Rieger C; Waller CF; Franke GN; le Coutre P; Kirchmair R; Junghanss C
Acta Haematol; 2020; 143(3):217-231. PubMed ID: 31590170
[TBL] [Abstract][Full Text] [Related]
12. [Ponatinib: new option for the treatment of resistant chronic myeloid leukemia].
Camañas-Troyano C; Calderón-Acedos C; Moriel-Sánchez Mdel C; Segura-Bedmar M
Farm Hosp; 2013; 37(5):428-9. PubMed ID: 24128110
[No Abstract] [Full Text] [Related]
13. Comparative expression analysis of dasatinib and ponatinib-regulated lncRNAs in chronic myeloid leukemia and their network analysis.
Kayabasi C; Caner A; Yilmaz Susluer S; Balci Okcanoglu T; Ozmen Yelken B; Asik A; Mutlu Z; Caliskan Kurt C; Goker Bagca B; Biray Avci C; Sahin F; Saydam G; Gunduz C
Med Oncol; 2022 Jan; 39(3):29. PubMed ID: 35059859
[TBL] [Abstract][Full Text] [Related]
14. Ponatinib reduces viability, migration, and functionality of human endothelial cells.
Gover-Proaktor A; Granot G; Shapira S; Raz O; Pasvolsky O; Nagler A; Lev DL; Inbal A; Lubin I; Raanani P; Leader A
Leuk Lymphoma; 2017 Jun; 58(6):1455-1467. PubMed ID: 27733071
[TBL] [Abstract][Full Text] [Related]
15. Safe and effective use of ponatinib in a patient with chronic myeloid leukemia and acute venous thromboembolism on therapeutic anti-coagulation.
Shomali W; Redmond C; Bogati S; Zimmerman C; Visconte V; Tabarroki A; Kalaycio M; Tiu RV
Leuk Lymphoma; 2016; 57(1):193-5. PubMed ID: 25942382
[No Abstract] [Full Text] [Related]
16. [Is AP24534 (Ponatinib) the next treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia?].
Thomas X
Bull Cancer; 2011 Jul; 98(7):761-7. PubMed ID: 21700550
[TBL] [Abstract][Full Text] [Related]
17. Novel TKI-resistant BCR-ABL1 gatekeeper residue mutations retain in vitro sensitivity to axitinib.
Lasater EA; Massi ES; Stecula A; Politi J; Tan SK; Smith CC; Gunthorpe M; Holmes JP; Chehab F; Sali A; Shah NP
Leukemia; 2016 Jun; 30(6):1405-9. PubMed ID: 26511402
[No Abstract] [Full Text] [Related]
18. Effects of bortezomib on ponatinib-resistant Philadelphia chromosome-positive cells.
Okabe S; Moriyama M; Gotoh A
Leuk Lymphoma; 2024 May; 65(5):696-699. PubMed ID: 38300854
[No Abstract] [Full Text] [Related]
19. Platelet dysfunction associated with ponatinib, a new pan BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitor therapy.
Neelakantan P; Marin D; Laffan M; Goldman J; Apperley J; Milojkovic D
Haematologica; 2012 Sep; 97(9):1444. PubMed ID: 22532521
[No Abstract] [Full Text] [Related]
20. Ponatinib: targeting the T315I mutation in chronic myelogenous leukemia.
Shah NP
Clin Adv Hematol Oncol; 2011 Dec; 9(12):925-6. PubMed ID: 22252660
[No Abstract] [Full Text] [Related]
[Next] [New Search]
